Environmental Impact Acquisition Corp.
Environmental Impact Acquisition — SPAC Merger (October 2021)
98 slides from Environmental Impact Acquisition's SPAC merger presentation, Oct 21, 2021
Slide 1: Science Day for investors October 19th 2021
Science Day for investors October 19th 2021 Exhibit 99.1
Slide 2: Legal disclaimer: Forward-Looking Statements
Legal disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws with respect to the business of GreenLight Biosciences, Inc., including statements regarding the anticipated benefits and uses of and market opportuniti
Slide 3: Legal disclaimer: Use of Projections
Legal disclaimer Use of Projections This presentation contains certain financial forecasts. Neither ENVI’s nor GreenLight’s independent auditors have studied, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this presentation, and,
Slide 4: Legal disclaimer: Important Information and Where to Find It
Legal disclaimer Important Information and Where to Find It This presentation may be deemed to relate to a proposed business combination between GreenLight Biosciences, Inc. and Environmental Impact Acquisition Corp. This presentation does not constitute either (a) a solicitation of a proxy, consent
Slide 5: Welcome to Science Day
Today’s Science Day aims to update investors on the company’s progress toward solving some of the world’s largest and most difficult problems by delivering on the full potential of RNA. You will see some of our best and brightest present and demonstrate that progress in our labs and greenhouses. Pro
Slide 6: More impact, for more people, in more of the world
More impact, for more people, in more of the world. GreenLight aims to solve some of the world’s largest and most difficult problems by delivering on the full potential of RNA. In this presentation you will learn about our progress towards that goal, but first, four noteworthy achievements: Platform
Slide 7: GreenLight has a clear purpose
We aim to achieve this goal through the design, development and production of RNA through our unique cell-free biomanufacturing platform including the know-how around it. This platform enables us to make complex biological molecules in a manner that we believe is capable of creating products at a lo
Slide 8: Humanity faces numerous challenges
Humanity faces numerous challenges. There are more than seven and a half billion people sharing the diminishing resources of Earth. This growing population needs to produce more food with the same amount of land and, at the same time, honor the global desire to replace chemical pesticides. Not only
Slide 9: RNA has gained broad global prominence
Ribonucleic acid, or RNA, has gained broad global prominence as the COVID-19 pandemic has swept through the world’s population, prompting messenger RNA, or mRNA, vaccines to move from a scientific theory to a medical reality. Vaccines made using mRNA proved among the fastest to develop and the easie
Slide 10: Our technology platform
Our technology platform, which was initially developed to produce dsRNA molecules for agricultural crop protection solutions and is protected by patents and know-how, is capable of synthesizing building blocks (nucleotides), building tools (enzymes), and instructions (DNA templates) to make dsRNA wi
Slide 11: Overview of RNA production technology
Overview of RNA production technology Drew Cunningham
Slide 12: RNA plays an essential role in biological processes
RNA 101 RNA plays an essential role in biological processes RNA building blocks (nucleotides) are assembled by an enzyme (RNA polymerase) into RNA according to a DNA template Transcription One form of RNA, messenger RNA (mRNA), carries information from DNA to the ribosome for translation. Product co
Slide 13: An example of RNA interference: Colorado potato beetle
An example of RNA interference How dsRNA works on the Colorado potato beetle (CPB) Mixed with water and sprayed using standard agricultural practice over crops, the RNA is used at a rate of a few grams per hectare. This is less than one-tenth the rate at which most conventional industrial chemicals
Slide 14: Timeline for lead dsRNA products
Timeline for lead dsRNA products 6 years from concept to anticipated registration of first product (for the Colorado potato beetle) 2017 Today Achieved active ingredient specifications & cost target with commercially viable process RNA process proof of concept IP filed Analytical methods established
Slide 15: Product development
Product development Identify Bioinformatics Tools such as machine learning and proprietary algorithms identify best gene target candidates to protect food crops, design advanced medicines and vaccines for human and animal health Develop and optimize Massive parallel trials High-throughput automation
Slide 16: Overview of dsRNA production technology for agriculture
Overview of dsRNA production technology for agriculture Cost less than $1/g dsRNA Scale +1,000 L batch for multi-kg-scale dsRNA RNA Building Blocks (NMPs) Enzyme (Nuclease) Instructions (DNA Template) Microbial RNA (e.g., yeast) Enzymes (Kinases, Polymerase) dsRNA Active Ingredient Energy (Polyphosp
Slide 17: Adapting the dsRNA process for mRNA
Adapting the dsRNA process for mRNA, leveraging know-how and expertise Analytical methods Data systems 2. GMP compliance & control of purity are required 1. mRNA requires a cap and tail 3. mRNA requires delivery to cells (e.g., via encapsulation in lipid nanoparticles)
Slide 18: COVID-19 vaccine program
COVID-19 vaccine program Antu K. Dey, Lorenzo Aulisa, Marcelo Samsa and Jennifer Raymond On behalf of COVID-19 Vaccine Program Team
Slide 19: Agenda of the presentation
Introduction to GLB’s COVID-19 vaccine program Vaccine delivery and formulation Pre-clinical design and evaluation Product development activities and GMP readiness for vaccine production Summary Agenda of the presentation Antu K. Dey Lorenzo Aulisa Marcelo Samsa Jennifer Raymond Antu K. Dey
Slide 20: Introduction
Introduction Antu K. Dey
Slide 21: A sobering reminder
Globally, as of October 15, 2021: 422,625 new cases 239,437,517 confirmed cases 4,879,235 Deaths A sobering reminder……….. Not since 1918 has the world been so affected by the emergence, spread, and death toll resulting from a respiratory virus. Source: World Health Organization EUA of mRNA vaccines
Slide 22: SARS-CoV-2 Spike protein and Ab-mediated protection
SARS-CoV-2 Spike (S) protein and Ab-mediated protection Approx. 90% of the plasma or serum neutralizing antibody activity targets the spike receptor-binding domain (RBD) [Piccoli, L. et al. Cell 183, 1024–1042 (2020)] Post (mRNA) vaccination sera showed that they target a range of RBD epitopes, simi
Slide 23: GreenLight COVID-19 vaccine product profile
Safety to be evaluated GreenLight COVID-19 vaccine: product profile under preclinical evaluation Adults Adolescents Children Target population Efficacy to be evaluated Stable vaccine LMICs (...global) Lower cost per dose
Slide 24: COVID-19 vaccine regulatory and clinical strategy
Regulatory (for Phase 1): File Investigational New Drug Application (IND) with FDA in United States Concurrently, file Clinical Trial Application (CTA) with SAHPRA in South Africa (and with other African Regulatory Agencies, as required) Clinical Studies: Phase I (in South Africa) Full-length Spike
Slide 25: Vaccine delivery and formulation
Vaccine delivery and formulation Lorenzo Aulisa
Slide 26: Barriers for successful delivery of RNA cargos
Barriers for successful delivery of RNA cargos Extracellular Barriers Intracellular Barriers Endonucleases Degradation Renal filtration and Mononuclear Phagocyte System (MPS) RNA Water soluble Bulky Anionic Charge Cell Membrane Endosomal Escape Cytosol Release
Slide 27: mRNA delivery technology landscape
mRNA delivery technology landscape (non-viral) PEGylation or other coatings Surface Functional Groups (-SH, -NH2, -COOH, …) Surface Charge Targeting Ligands (Antibody, Peptides, Aptamer, …) Nanoparticles Size Surface Shape Material
Slide 28: Development of lipid-based systems for nucleic acid delivery
Onpattro First siRNA drug approved by FDA based on LNP delivery Rapid summary in the development of lipid-based systems for nucleic acid delivery 1965 Development of liposomes 1978 Development of liposomes-mRNA formulations 1996 DOTAP Bio- degradable version of DOTMA 1987 DOTMA, cationic lipid for D
Slide 29: Key stages of LNP production and process development
Key stages of LNP production and process development Solution preparation Drug load Buffer Temperature Lipids Solvent Temperature LNP manufacturing Buffer exchange LNP concentration Sterile filtration Process Mixing device Mixing chip Dilution buffer Temperature TFR and FFR Dialysis Membrane Buffer
Slide 30: Lipids and their role in the COVID drug product
Lipids and their role in the COVID drug product (DP) Ionizable Lipid Cholesterol Phospholipid PEG-Lipid Organic Phase Mixing Time Polarity Acidic Water Phase
Slide 31: Preclinical design and evaluation
Preclinical design and evaluation Marcelo Samsa
Slide 32: GLB's COVID-19 vaccine design
GLB-COV-2_042 Wuhan-Spike WT-FL 3’ UTR (Cap) (PolyA) 5’ UTR Wuhan-Spike WT-FL 3’ UTR (Cap) (PolyA) 5’ UTR GLB-COV-2_043 GLB’s COVID-19 vaccine design Two mRNA vaccines were rapidly designed and developed: GLB-COV-2_042 & GLB-COV-2_043 RNA synthesis & formulation DNA sequence selection & synthesis An
Slide 33: Promising antibody response in mice
SARS-COV-2 Humoral Responses (Neutralization & Binding Titers) Day 0 21 42 >42 Vaccination Bleed 28 Promising antibody response for GreenLight COVID-19 vaccine candidates in mice GreenLight candidates induced humoral responses exceeding WHO standard
Slide 34: Promising cell-mediated immunity in mice
Promising cell-mediated immunity for GreenLight COVID-19 vaccine candidates in mice GreenLight candidates induced Th1-biased cell mediated immune responses SARS-COV-2 Cellular responses (T-cell restimulation)
Slide 35: Promising disease protection results in hamsters
Promising disease protection results for GreenLight COVID-19 vaccine candidates in hamsters All tested doses protected against morbidity 0 21 56 39/42 COVID-19 Challenge Viral burden & histopathology 44 46 Tissue
Slide 36: Next COVID-19 vaccine under preclinical evaluation
Next COVID-19 vaccine (under preclinical evaluation) Beta-Spike FL_2P (B.1.351) 3’ UTR (PolyA) 5’ UTR Delta-Spike FL_2P (B.1.617.2) 3’ UTR (PolyA) 5’ UTR Alpha-Spike FL_2P (B.1.1.7) 3’ UTR (PolyA) 5’ UTR Gamma-Spike FL_2P (P.1) 3’ UTR (PolyA) 5’ UTR X-Spike FL_2P (X) 3’ UTR (PolyA) 5’ UTR Kappa-Spik
Slide 37: Product development activities and GMP readiness
Product development activities and GMP readiness for vaccine production Jennifer Raymond
Slide 38: From innovative science to First Time in Human
✔ Initiate Tox Study July 2021 March 2022 From innovative science to First Time in Human (FTiH) PreClinical GLP Qualified Assays Protocols CRO, Labs Characterization ✔ Facility move in ready Equipment Process Dev Clinical Scale Eng. Run November 2021 Qualification IOQ SOP; MBR Clinical GMP DS Produc
Slide 39: Summary
Summary – Antu K. Dey
Slide 40: Summary
From the learnings of RNA production for Plant Health business, the Human Health division has developed a phase-appropriate mRNA production process for GLB's COVID-19 vaccine to support the clinical development program. The pre-clinical team has demonstrated that GLB’s COVID-19 vaccine induced stron
Slide 41: In vivo targeted RNA-based gene therapy for Sickle Cell Disease
In vivo targeted RNA-based gene therapy for Sickle Cell Disease Human Health - Gene Therapy Program
Slide 42: The potential of gene therapy
Signal Transduct Target Ther (2021) Gene therapy has the potential to provide safe, effective, and curative treatments for genetic diseases The potential of gene therapy Restoring a missing or mutated protein Training the immune system to fight disease Silencing disease-causing mutations
Slide 43: Key limitations with current technologies
Key limitations with current technologies Cusabio Nat. Rev. Drug Discov. (2019) Nature (2013) Gene Therapy (2010) Ex vivo treatments are costly and invasive Viral vectors require high doses, multiple treatments Viral vectors are immunogenic Gene editing is restricted to dividing cells
Slide 44: GreenLight's goals
GreenLight’s goals Challenges with existing technologies GLB gene therapy program goals Gene editing by CRISPR only occurs in dividing cell populations, precluding stem cells Current therapies require ex vivo cell engineering, which is invasive and costly Multiple doses required to achieve clinical
Slide 45: Differentiating our approach from CRISPR and lentiviruses
Non-viral (RNA/DNA-based) Cell-free manufacturing Integrating new genetic material requires cell division (HR) Replication-deficient viral vector Produced in mammalian cell lines Integrates into dividing & non-dividing cells Non-viral (RNA-based) Cell-free manufacturing Encodes lentiviral enzymes to
Slide 46: Sickle cell disease and GreenLight gene therapy architecture
Nature (2018) Frontier (2020) Sickle cell disease disproportionately affects the developing world GreenLight gene therapy architecture targets potential solutions that: Can edit dividing and nondividing cells Do not require viral vectors Achieves long-lasting effect Are delivered direct to the patie
Slide 47: Accelerated timeline for sickle cell disease gene therapy
Bill & Melinda Gates Foundation agreement Expand HH labs in Woburn Evidence of minimal gene therapy system expression May 2020 Jan 2021 Today Cell culture capabilities @ GL Foundational application filing for RNA based gene therapy Test function of initial RNA designs Kelsey Greg Steve Miryam Sweta
Slide 48: Goals for Gates Foundation sickle cell disease collaboration
Aim 1. Validate RNA-based designs for integration & gene expression in vitro Design, manufacture and screen in cell culture model – ongoing Testing in non replicating cells Aim 2. Demonstrate integration & gene expression in vivo in mouse models In vivo ‘integration’ demonstration – initial tests of
Slide 49: Potential mechanism for our gene therapy architecture
Ribosome Cell Nucleus Target RNA-encoded instructions Target specific vehicle Can edit dividing and nondividing cells Do not require viral vectors Achieves long-lasting effect Are delivered direct to the patient Can be manufactured at scale GreenLight gene therapy architecture targeting potential so
Slide 50: Tools created by GreenLight
Tools created by GreenLight RNA-encoded instructions Functional Unit Validation =>> Construct library down-selection Actin IN + Optimized Integrase - Poly(A) +Poly(A) Functional analyses Protein Expression RNA Manufacturing, Quality analyses Integrase Nuclei Actin lgDNA copies p66 p51 Actin Optimize
Slide 51: Evidence of transgene expression
Evidence of transgene expression Cell lines were transfected with: lgRNA template encoding nanoluciferase reporter functional unit mRNAs encoding RT and IN Control – lgRNA template only Evidence of Nanoluciferase expression above template only control Nanoluciferase lgRNA lgRNA + functional units
Slide 52: In summary: key highlights from Gene Therapy Program
In summary Key highlights from our Gene Therapy Program Received funding from the Gates Foundation Established cell culture facilities and capabilities Recruited a team with expertise in gene therapy and editing Filed foundational patent application for RNA-based gene therapy Designed 150 constructs
Slide 53: ASG .
te ts ra ASG . 2 Plant Mgaith presentation ' > |
Slide 54: Botrytis control with dsRNA
Botrytis control with dsRNA Kestrel McCorkle Fungicide Discovery
Slide 55: dsRNA for Disease Management outline
dsRNA for Disease Management Selecting of Targets Screening and Hits Active Sequences and Supporting Data Field Studies Next Steps Outline
Slide 56: Why should we care?
Why should we care? Fungal pathogens cause 17-30% crop loss on average to 5 major food crops Specific challenges for controlling botrytis, which causes gray mold: Wide host range, wind-dispersed spores Fungicide resistance Multiple applications required from bloom through harvest Fungal disease prob
Slide 57: GreenLight's technology can help
GreenLight’s technology can help dsRNA Addressing fungicide resistance dsRNA designed to silence gene targets Easily stack triggers to silence multiple genes Limited potential for long-term environmental persistence Targeted control
Slide 58: How are we going to solve botrytis in the field?
Picking fungal essential gene targets Select dsRNA sequences Robotic High-Throughput Production In vitro screening & MOA confirmation In vivo screening Greenhouse Field How are we going to solve the problem of botrytis in the field?
Slide 59: Machine learning supports dsRNA sequence design
Machine learning supports dsRNA sequence design Brainstorming session Novel Gene Targets (Novel Target Miner) Transcript from target gene of interest Get a subsequence without any hits to Non-Target Organisms Predict Silencing Efficacy Contiguous segment with high predicted efficacy Final Design mRN
Slide 60: Robotic high-throughput production
Robotic high-throughput production allows screening of up to 1,000+ initial candidates Cell-free allows for low-cost, larger-scale production of lead candidates for greenhouse tests, formulation development, etc. Robotic high-throughput production for all candidates Cell-free production for lead can
Slide 61: Candidates narrowed down through increasingly demanding screening
10.3% of candidates in vitro and 9.9% of candidates in vivo attained target threshold to advance In vivo screening 191 candidate sequences screened 9.9% attained target threshold 19 nominated for greenhouse testing In vitro screening 969 candidate sequences screened 10.3% attained target threshold 1
Slide 62: Greenhouse screening of dsRNA
Select dsRNA sequences Robotic High-Throughput Production In vitro screening & MOA confirmation In vivo screening Greenhouse Field Initial screening performed on a dwarf tomato variety in the greenhouse Whole plant screening Two initial rates are selected per hit for screening on tomato plants and s
Slide 63: Naked dsRNA on tomato plants cuts disease severity
Application of naked dsRNA to whole tomato plants in greenhouse cuts disease severity Sequence 2, without enhancement from formulation, reduces severity by 46-59% compared to untreated control Data compiled over two biological runs (n=20) Tomato plants treated with Sequence 2, then inoculated 24 hou
Slide 64: Optimization in the field
Optimization in the field Non-formulated and formulated dsRNA optimized for the lowest use rate that delivers viable potency and persistence Gene Target Selection Robotic High-Throughput Production In vitro screening & MOA confirmation In vivo screening Greenhouse Field Seq2 GreenLight sequences wit
Slide 65: Strawberries treated suffer less severe disease
Strawberries treated without enhancement from formulation suffer less severe disease % Disease severity of Botrytis on strawberries Treatments applied every 3-4 days (twice/week) or every 7 days (once/week) – >4 applications Trials conducted in New York and Italy, respectively GLB leads demonstrate
Slide 66: Next steps in 2021
Next steps in 2021 Field studies started at the end of August and September, and will begin on strawberries again in December 1. Continue studies in the field Sequence 2: Rates 6-50 g ai/ha In combination with two formulations Add spray interval of 7 days 2. Improvements Rates 6-50 g ai/ha Formulati
Slide 67: Takeaways
Takeaways New capabilities Field testing Up next Why should we be EXCITED? High-throughput production of dsRNA triggers High-throughput screening in vitro Developed greenhouse assay Commercially viable formulations found Successful trials for botrytis on strawberries conducted Sequence 2 was active
Slide 68: Developing dsRNA to combat the Varroa destructor
Developing dsRNA to combat the Varroa destructor By Katie Harrigan
Slide 69: Agenda
Introduction: the story of modern beekeeping in the US and the Varroa mite GreenLight’s first field trial with honeybees: design and data Upcoming trials Agenda
Slide 70: Introduction: modern beekeeping and the Varroa mite
Introduction: the story of modern beekeeping in the US and the Varroa mite
Slide 71: Honeybees are critical to almond pollination
Honeybees are critical to almond pollination Many other commercial crops are also dependent on honeybee pollination services In the U.S. commercial honeybees are known as the Western Honeybee or the European Honeybee - Apis mellifera US honeybees are responsible for the commercial pollination of alm
Slide 72: The external parasitic mite attacks honeybees
The external parasitic mite attacks and feeds on honeybees Every hive in US has or will have Varroa destructor (Varroa mite) Originally only on the Eastern honeybee (Apis cerana) but now attacks the Western honeybee (Apis mellifera) Vectors diseases of many bee viruses such as deformed wing virus, a
Slide 73: Chemical controls for Varroa and their limitations
Table information sourced from Honey Bee Health Coalition Brand Name Active ingredient Efficacy Resistance? Harmful to bees? Apistan Tau-fluvalinate (pyrethroid) *** Apivar Amitraz *** CheckMite+ Coumaphos (organophosphate) *** Mite-Away Quick Strips (MAQS) Formic acid (organic acid) ** Api bioxal O
Slide 74: GreenLight's first field trial with honeybees
GreenLight’s first field trial with honeybees: design and data
Slide 75: 40% fewer Varroa mites with GS15 versus chemical control
40% fewer Varroa destructor mites at 12 weeks in hives with GS15 compared with leading chemical control product Our first Varroa mite trial in Spring 2021 proved EP15 efficacy using GLB manufacturing Spring trials were set up based on Bayer’s data and prior learnings Goals Assess efficacy of GS15 wi
Slide 76: Higher brood and health scores with 8g/l application
Higher brood and health scores compared to chemical controls with 8g/l application Model: Generalized Linear Mixed Model, Distribution: Poisson, Link Function: Log Fixed effects: Treatment + Location + Treatment * Location Random effects: Location [Plot] and Plot [Hive] 1. Control 2. Chemical Contro
Slide 77: Succession of GLB GS15 field trials
Further goals of 2022 trials are to inform product use, better inform product positioning and marketing strategy Succession of GLB GS15 Field Trials Planning has started for longer-term 2022 field trials to understand overwintering success Spring 2021 results Fall 2021 Results Field Trial 1 2022: Ov
Slide 78: Snapshot of the Plant Health discovery pipeline
Snapshot of the Plant Health discovery pipeline Ron Flannagan Vice President, Plant Health R&D
Slide 79: Fusarium spoils up to $1b worth of wheat annually
Fusarium, which produces Vomitoxin (DON), spoils up to $1b worth of wheat annually in the US GreenLight is working with sequences that show promise for controlling Fusarium Fusarium Head Blight (FHB) An important fungal disease of wheat and small grains, caused by a Fusarium pathocomplex Total Addre
Slide 80: First sequences show promise against Fusarium in vitro
First sequences show promise with direct application to fusarium 25% to 40% reduction of in vitro Fusarium, relative to untreated Standardized % control relative to untreated Fusarium With Software Analysis Microscope Acquired Image
Slide 81: Reduction of Vomitoxin and Fusarium on wheat seedlings
First sequences show promise with application on infected wheat seedlings 25% to 50% reduction of Vomitoxin (DON) and Fusarium, relative to untreated % reduction relative to untreated Disease DON GS1901 50PPM GS1909 50PPM Fungicide 10PPM Two approaches to controlling FHB: 1) DON reduction and 2) Fun
Slide 82: Coleopteran pest, EU market and strategic value
Coleopteran pest, EU market and strategic value Pollen beetle is primary pest of oilseed rape Growers treat with a single spray application at bud stage when pollen beetle is the only pest present Few conventional chemistry alternatives Neonicotinoids: most are banned in EU Indoxacarb: current solut
Slide 83: Pollen beetle mortality in vitro
First sequences drive statistically significant pollen beetle mortality Lab study shows 20% to 80% pollen beetle mortality in vitro * * * * * * * * * * * * * * * * in vitro
Slide 84: Pollen beetle mortality in vivo
40% pollen beetle mortality in vivo relative to untreated control * * * * * First sequences show promise with application on oilseed rape plants
Slide 85: Two spotted spider mite and resistance
The polyphagous pest, managed in greenhouse and field settings, rapidly develops resistance to conventional insecticides Two spotted spider mite has a wide crop host range, consumes many fruits and vegetables Total Addressable Market for acaricide: $1.1b Two spotted spider mite (TSSM) > $250m worldw
Slide 86: Spider mite survival near zero in vitro
Adult females survival near zero in vitro within 10 days of application to leaf disc First sequences drive statistically significant mortality rates of TSSM In collaboration with university partner dsRNA applied to surface TSSM survival curve
Slide 87: Control of diamondback moth and fall armyworm
To date, ingested dsRNA not viable for control of diamondback moth (DBM) and fall armyworm (FAW) GreenLight progress toward dsRNA control of Lepidoptera Diamondback moth Total Addressable Market: $890m Fall armyworm Total Addressable Market: $1.9b (not included in projections) Multiple asynchronous
Slide 88: Delivery technology increases dsRNA impact
Approach enables a 50% increase in diamondback moth mortality and 90% lower weight in fall armyworm larvae, compared to naked dsRNA Delivery technology under evaluation increases impact of dsRNA sequences * * Key Milestones Optimize delivery technologies to overcome target barriers Demonstrate activ
Slide 89: Powdery mildew is the largest driver for pesticide use in viticulture
Powdery mildew is the largest driver for pesticide use in viticulture Total addressable market for grape powdery mildew is $1.4b globally Grape powdery mildew (PM) caused by Erysiphe necator is economically important in the global crop protection market. On average seven fungicide treatments are ro
Slide 90: Powdery mildews can only be screened in vivo
Powdery mildews can only be screened in vivo or on whole plants Powdery mildew only infects grape vines Fungal biomass and spore production quantification All assays must be performed on plants or plant tissue due to the obligate nature of pathogen Initial leaf disc screening performed at USDA-Genev
Slide 91: GreenLight sequence demonstrates control equivalent to commercial standards
GreenLight sequence demonstrates control equivalent to commercial standards Lab results translates to field level control consistent with commercial standards % Disease severity of Powdery Mildew on grapes Treatments applied every 3-4 days (twice/week) or every 7 days (once/week) throughout season D
Slide 92: GL43 disease control in Dundee, New York trial
Disease incidence – % of leaves that show symptoms Disease severity – % of the leaf impacted by disease GL43 disease control ≥ commercial standards at all weekly assessments GL43 level of control increased as trial progressed GL43 demonstrated > control on fruit than either of the commercial standar
Slide 93: Fungal projects advancing rapidly
Fungal projects advancing rapidly Powdery mildew demonstrating field activity: Phase/Gate pipeline advancement – PoC to PoT (through Gate A) Fusarium concepts demonstrated in key lab assays Program Collaborator Discovery & lab studies Greenhouse trials Confirmatory trials POC field trials Diamondbac
Slide 94: Questions
Questions
Slide 95: Business overview
Susan Keefe CFO Business overview
Slide 96: Global product portfolio addresses key food and agriculture concerns
Global product portfolio addresses key food and agriculture industry concerns 7 Product Launches by 2026 $6B 2026E Addressable Markets High-priority geographies for xxx x x x x xxxxx CPB Potatoes Pollinator Bee hives Botrytis Most fruit and vegetables DBM Cabbage Fusarium Wheat TSSM Most fruit and v
Slide 97: Plant health revenue: business plan
Plant health revenue: business plan ($ in millions) Products in market 0 0 1 2 7 8 8 GLB Product Revenue R&D Collab. Revenue Platform Mfg. Revenue $0.0 $0.6 $5.2 $18.9 $119.7 $320.7 Target gross margin of 75-90%1 for 2025 and beyond 1. Target gross margin is for products GreenLight distributes direc
Slide 98: End of Science Day presentation
END OF SCIENCE DAY PRESENTATION October 19, 2021
Environmental Impact Acquisition — SPAC Merger (October 2021) on 6ix